Table 2. League Table Showing Indirect Comparisons Among Second-Line Treatmentsa.
| Treatment | Progression-free survival | |||||
|---|---|---|---|---|---|---|
| Overall survival | Regorafenib | 1.04 (0.79-1.36) | 0.64 (0.47-0.87) | 0.74 (0.56-0.98) | 0.46 (0.37-0.57) | |
| 0.82 (0.62-1.07) | Cabozantinib | 0.61 (0.46-0.82) | 0.71 (0.55-0.92) | 0.44 (0.37-0.53) | ||
| 0.79 (0.58-1.08) | 0.97 (0.71-1.33) | Pembrolizumab | 1.16 (0.86-1.56) | 0.72 (0.57-0.90) | ||
| 0.71 (0.54-0.93) | 0.87 (0.67-1.14) | 0.90 (0.66-1.22) | Ramucirumab | 0.62 (0.52-0.74) | ||
| 0.70 (0.51-0.96) | 0.85 (0.62-1.17) | 0.88 (0.62-1.25) | 0.98 (0.71-1.34) | Brivanib | ||
| 0.62 (0.51-0.75) | 0.76 (0.63-0.92) | 0.78 (0.61-1.00) | 0.87 (0.72-1.05) | 0.89 (0.69-1.15) | Placebo | |
a
Hazard ratios (HRs) and 95% CIs for the pairwise comparisons of the network meta-analysis from indirect comparisons. Comparisons should be read from left to right. The HRs for comparisons are in the cell in common between the column-defining and row-defining treatment. For progression-free survival, an HR of less than 1 favors row-defining treatment. For overall survival, an HR of less than 1 favors column-defining treatment.